retatrutide approval status october 2025 approval: FDA status, clinical trial results, and when it could be available What Is Retatrutide for Weight

In the Phase 2 retatrutide trial published in the New England Journal of Medicine (2023), participants at the highest dose (12 mg) achieved a mean body weight reduction of approximately 24.2% over 48 weeks

Steven Swengel Dermatologist Board-Certified Dermatologist What To Expect During Your Weight Loss Treatment Our GLP-1 weight loss program is designed to help you lose weight quickly and safely

For this population, orforglipron is not just an alternative

Large outcomes trials have not shown a significantly higher pancreatitis incidence with GLP-1 RAs versus placebo, but the labeling still lists it as a warning

In a phase III study, semaglutide resulted in greater than 15% weight reduction from baseline (Wadden et al

Patients with severe gastrointestinal motility disorders (such as gastroparesis), history of bowel obstruction, or significant abdominal surgical history should discuss their potential increased risk with their provider before starting weight loss injections